Abstract 14: Analysis of tumor DNA in urine as a highly sensitive liquid biopsy for patients with non-muscle invasive bladder cancer (NMIBC)
Matthew J. Resnick(Vanderbilt University Medical Center), Phillip G. Febbo(Veracyte (United States)), Michael Bonham(University of California, San Francisco), Richard D. Abramson(Genomic Health (United States)), Chris Silk(Genomic Health (United States)), Margarita Lopatin(Scion), Michael Crager(Providence Saint Joseph Medical Center), Kim M. Clark-Langone(Genomic Health (United States)), Neal D. Shore(Carolina Urologic Research Center), Seth Michelson(Genomic Health (United States)), Haluk Tezcan(Genomic Health (United States)), Po N. Lam, Gregory E. Alexander(Genomic Health (United States))
Cited by 2
Related Papers
Gene expression correlates of clinical prostate cancer behavior
|Cancer Cell|2002|2.5k
The translational landscape of mTOR signalling steers cancer initiation and metastasis
|Nature|2012|1.4k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975